Latest Articles about MYGN

CE Mark for STJ's ILUMIEN OPTIS - Analyst Blog

Zacks Equity Research — Fri, 17 May 2013 22:29:42 Z

Medical devices major, St. Jude Medical Inc. ( STJ ) has won CE Mark approval for its ILUMIEN OPTIS Percutaneous Coronary Intervention (PCI) Optimization System. This intravascular imaging

Stryker Reiterated at Neutral - Analyst Blog

Zacks Equity Research — Fri, 17 May 2013 21:30:29 Z

On May 16, we retained Stryker Corp. ( SYK ) at Neutral, following its first-quarter results. Stryker's reported solid sales in the U.S. but international markets, especially Europe, still

SGEN's Adcetris under FDA Review - Analyst Blog

Zacks Equity Research — Fri, 17 May 2013 00:29:37 Z

Seattle Genetics, Inc. ( SGEN ) recently announced that the US Food and Drug Administration (FDA) has accepted its supplemental biologics license application (sBLA) seeking approval of

Covidien Prices Senior Notes - Analyst Blog

Zacks Equity Research — Thu, 16 May 2013 17:29:17 Z

Healthcare major, Covidien plc ( COV ) announced that its fully-owned subsidiary Covidien International Finance S.A. (CIFSA) will be offering 2.950% underwritten senior notes due 2023 for

Myriad Soars Higher on Celeb Clout - Analyst Blog

Zacks Equity Research — Wed, 15 May 2013 22:27:06 Z

Shares of Myriad Genetics Inc. ( MYGN ) touched a new 52-week high of $34.70 on Tuesday, May 14, 2013 following news out of Hollywood. Academy Award winning Hollywood star Angelina Jolie

The Angelina Jolie Connection: The Debate Over Patenting Human Genes

Josh Wolonick — Wed, 15 May 2013 21:33:00 Z

Yesterday, Angelina Jolie published an op-ed in the New York Time entitled "My Medical Choice," in which she explained her decision to undergo a preventive double mastectomy, having

Genomic Gains Coverage for DCIS - Analyst Blog

Zacks Equity Research — Mon, 13 May 2013 23:17:06 Z

Genomic Health Inc. ( GHDX ) continues to make strides towards establishing coverage for its Oncotype DX breast cancer test. The company disclosed that the assigned contractor for its

Earnings Beat for PETS, Margins Up - Analyst Blog

Zacks Equity Research — Mon, 13 May 2013 18:19:02 Z

America's largest pet pharmacy, PetMed Express ( PETS ) reported earnings of 23 cents per share in the fourth quarter of fiscal 2013, 2 cents ahead of the Zacks Consensus Estimate and up

GHDX Reports Loss, Beats on Revs - Analyst Blog

Zacks Equity Research — Mon, 13 May 2013 18:18:48 Z

Genomic Health ( GHDX ) reported first-quarter 2013 net loss of $0.9 million, down from a net income of $0.8 million in the year-ago period. The company's reported loss of 3 cents per share

MYGN Earnings Easily Beat, Guidance Up - Analyst Blog

Zacks Equity Research — Thu, 09 May 2013 01:25:01 Z

Myriad Genetics Inc. ( MYGN ) reported earnings per share (EPS) of 46 cents in the third quarter of fiscal 2013, representing a beat of 17.9% over the Zacks Consensus Estimate and EPS

Meridian Bioscience Inc. (VIVO) Ex-Dividend Date Scheduled for May 01, 2013

NASDAQ.com News — Tue, 30 Apr 2013 17:00:04 Z

Meridian Bioscience Inc. ( VIVO ) will begin trading ex-dividend on May 01, 2013. A cash dividend payment of $0.19 per share is scheduled to be paid on May 14, 2013. Shareholders who purchased

Myriad Downgraded to Neutral - Analyst Blog

Zacks Equity Research — Thu, 18 Apr 2013 23:10:46 Z

On Apr 17, we downgraded our recommendation on Myriad Genetics Inc. ( MYGN ) to Neutral from Outperform. Despite the recent healthy growth, the stock is presently out of favor on account of

Myriad's New Alliance for HRD Test - Analyst Blog

Zacks Equity Research — Thu, 28 Mar 2013 22:27:42 Z

Recently, Myriad Genetics Inc. ( MYGN ) inked an agreement with PharmaMar, a leading developer of marine-derived drugs, for the first publicly acknowledged commercial partnership for its

Myriad Retained at Outperform - Analyst Blog

Zacks Equity Research — Fri, 08 Mar 2013 19:50:01 Z

On Mar 5, 2013, we reaffirmed our long-term Outperform recommendation on Myriad Genetics Inc. ( MYGN ) following its strong second-quarter fiscal 2013 results and upward revision in the

Positive Data on Myriad's Prolaris - Analyst Blog

Zacks Equity Research — Thu, 07 Mar 2013 00:55:01 Z

Myriad Genetics Inc. ( MYGN ) revealed favorable findings for its Prolaris test for the diagnosis of prostate cancer in patients. The findings of the study entitled 'Validation of a panel